The POCT market is large and has enjoyed sound growth. From 2008 to 2018, the sales volume of the global POCT market doubled, with an average annual compound growth rate of 7.5%. The global POCT sales volume in 2021 was $31.5 billion.
Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.
Leinco Technologies, a leading global provider of in vitro diagnostic (IVD) raw materials, today announced the acquisition of BioClin, Inc.’s proprietary antibody clones used as IVD raw materials. This strategic partnership significantly expands Leinco’s portfolio of critical reagents for endocrine hormone research and diagnostic assays.
Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced that it has completed its previously announced acquisition of Akoya Biosciences, Inc., establishing a scaled leader in the early detection of disease for the neurology, oncology and immunology markets.
Noul said it has signed a memorandum of understanding (MOU) with Seegene Brazil to introduce its AI-based cervical cancer diagnostic solution, miLab CER, to the Brazilian market.
MedMira Inc. (MedMira) (TSXV: MIR) and REACH Nexus are excited to announce a clinical trial has officially started earlier than anticipated to evaluate MedMira’s Multiplo® TP/HIV rapid test for use as a self-test in Canada.
China enacted new measures, effective immediately, targeting the procurement of certain medical devices imported from the European Union in government purchasing programs, according to a notice issued by the Ministry of Finance on Sunday.
Thermo Fisher Scientific, the world leader in serving science, today announced the U.S. Food and Drug Administration (FDA) has approved the Oncomine™ Dx Express Test on the Ion Torrent™ Genexus™ Dx Integrated Sequencer as an in vitro diagnostic (IVD) assay for use as a companion diagnostic (CDx) for Dizal’s ZEGFROVY® (sunvozertinib) and in tumor profiling. This approval brings rapid next-generation sequencing (NGS) to decentralized clinical settings closer to where patients receive care. With the ability to deliver essential genomic insights in as little as 24 hours*, this approval helps advance the accessibility of precision oncology tools and enables more timely decision making.
The TOBY Test has received breakthrough device designation from the FDA for the early detection of bladder cancer. This designation underscores the significant potential of this innovative urine-based assay to fundamentally alter the landscape of bladder cancer detection and surveillance, offering a much-needed non-invasive alternative to current diagnostic paradigms.
Merck, a leading science and technology company, today announced that it has closed the acquisition of SpringWorks Therapeutics, Inc., for an enterprise value of $3.4 billion (approximately €3 billion)*, following regulatory clearances and the fulfillment of other customary closing conditions.
Molecular diagnosis is performed at the gene level with nucleic acids as the object for detection, with high sensitivity and accuracy.
Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.
Don’t miss important updates about the show and the in vitro diagnostic industry.
Sign-up for our newsletter today.
Copyright © 2025 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.